文献速递骨软组织肉瘤与黑色素瘤

使用新型影像分析对接受免疫治疗的黑色素瘤患者总生存期进行早期判读

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.
PubMed 文献 · JAMA Oncol · 2022-01-01

该预后研究利用影像组学和机器学习,回顾性分析KEYNOTE-002和KEYNOTE-006两项多中心临床试验中575例晚期黑色素瘤患者的基线和首次随访CT图像及临床元数据,构建并验证一个由4个影像特征组成的签名,用于估算接受帕博利珠单抗治疗患者的总生存期。在验证集287例接受帕博利珠单抗治疗的患者中,该签名估算第6个月界标时总生存状态的AUC为0.92(95%CI 0.89-0.95),而RECIST 1.1标准的AUC为0.80(95%CI 0.75-0.84)。

要点

  • 影像组学签名由4个影像特征组成,其中2个与肿瘤大小相关,2个反映肿瘤影像表型变化。
  • 在验证集287例接受帕博利珠单抗治疗的患者中,签名估算总生存状态的AUC为0.92(95%CI 0.89-0.95)。
  • RECIST 1.1标准估算总生存状态的AUC为0.80(95%CI 0.75-0.84)。

核心结论

  • 研究结果表明,基于基线及首次随访常规CT图像得出的影像组学签名,或可在临床中用于对接受单药PD-1阻断治疗的黑色素瘤患者未来总生存概率进行准确的早期判读。

研究设计与样本

  • 该预后研究采用影像组学和机器学习,回顾性分析基线和首次随访CT图像及相关临床元数据。
  • 数据来自KEYNOTE-002(2017年分析)和KEYNOTE-006(2016年分析)两项多中心临床试验的前瞻性收集数据。
  • 纳入575例晚期黑色素瘤患者,随机分配至训练集和验证集;数据收集时间为2012年11月20日至2019年6月3日,分析时间为2019年7月1日至2021年9月15日。

主要发现

  • 随机森林模型从CT图像分割肿瘤提取的25个影像特征中,识别出由4个影像特征组成的最佳估算总生存期的签名,其中2个与肿瘤大小相关,2个反映肿瘤影像表型变化。
  • 在验证集287例接受帕博利珠单抗治疗的患者中,该签名估算第6个月界标时总生存状态的AUC为0.92(95%CI 0.89-0.95)。
  • RECIST 1.1标准估算总生存状态的AUC为0.80(95%CI 0.75-0.84),并将肿瘤结局分类为部分或完全缓解93/287(32.4%)、疾病稳定90/287(31.3%)或疾病进展104/287(36.2%)。

临床怎么用

  • 作者认为,基于基线和首次随访常规CT图像的影像组学签名或可在临床环境中用于对接受单药PD-1阻断治疗的黑色素瘤患者未来总生存概率进行准确的早期判读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Existing criteria to estimate the benefit of a therapy in patients with cancer rely almost exclusively on tumor size, an approach that was not designed to estimate survival benefit and is challenged by the unique properties of immunotherapy. More accurate prediction of survival by treatment could enhance treatment decisions. OBJECTIVE: To validate, using radiomics and machine learning, the performance of a signature of quantitative computed tomography (CT) imaging features for estimating overall survival (OS) in patients with advanced melanoma treated with immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used radiomics and machine learning to retrospectively analyze CT images obtained at baseline and first follow-up and their associated clinical metadata. Data were prospectively collected in the KEYNOTE-002 (Study of Pembrolizumab [MK-3475] Versus Chemotherapy in Participants With Advanced Melanoma; 2017 analysis) and KEYNOTE-006 (Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab [MK-3475] Compared to Ipilimumab in Participants With Advanced Melanoma; 2016 analysis) multicenter clinical trials. Participants included 575 patients with a diagnosis of advanced melanoma who were randomly assigned to training and validation sets. Data for the present study were collected from November 20, 2012, to June 3, 2019, and analyzed from July 1, 2019, to September 15, 2021. INTERVENTIONS: KEYNOTE-002 featured trial groups testing intravenous pembrolizumab, 2 mg/kg or 10 mg/kg every 2 or every 3 weeks based on randomization, or investigator-choice chemotherapy; KEYNOTE-006 featured trial groups testing intravenous ipilimumab, 3 mg/kg every 3 weeks and intravenous pembrolizumab, 10 mg/kg every 2 or 3 weeks based on randomization. MAIN OUTCOMES AND MEASURES: The performance of the signature CT imaging features for estimating OS at the month 6 posttreatment landmark in patients who received pembrolizumab was measured using an area under the time-dependent receiver operating characteristics curve (AUC). RESULTS: A random forest model combined 25 imaging features extracted from tumors segmented on CT images to identify the combination (signature) that best estimated OS with pembrolizumab in 575 patients. The signature combined 4 imaging features, 2 related to tumor size and 2 reflecting changes in tumor imaging phenotype. In the validation set (287 patients treated with pembrolizumab), the signature reached an AUC for estimation of OS status of 0.92 (95% CI, 0.89-0.95). The standard method, Response Evaluation Criteria in Solid Tumors 1.1, achieved an AUC of 0.80 (95% CI, 0.75-0.84) and classified tumor outcomes as partial or complete response (93 of 287 [32.4%]), stable disease (90 of 287 [31.3%]), or progressive disease (104 of 287 [36.2%]). CONCLUSIONS AND RELEVANCE: The findings of this prognostic study suggest that the radiomic signature discerned from conventional CT images at baseline and on first follow-up may be used in clinical settings to provide an accurate early readout of future OS probability in patients with melanoma treated with single-agent programmed cell death 1 blockade.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dercle L, Zhao B, Gönen M, et al. Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. JAMA Oncol. 2022. PMID: 35050320. doi:10.1001/jamaoncol.2021.6818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。